Background: High-dose therapy and autologous stem cell transplantation (ASCT) is often considered for older patients (age >60 years) with relapsed/refractory aggressive lymphomas. Although registry data support the safety and potential efficacy of this approach, there are no prospective trials evaluating outcomes of ASCT in older patients. We evaluated the result of second-line chemotherapy and ASCT in older versus younger patients in the CCTG randomized LY.12 trial.
Introduction
High-dose therapy followed by autologous stem cell transplant (ASCT) is the recommended treatment of selected patients with relapsed or refractory aggressive lymphomas responding to second-line (salvage) chemotherapy. The landmark study demonstrating superiority of this approach over chemotherapy alone restricted eligibility to patients under the age of 60 years [1] . Although registry data and retrospective studies report benefit from ASCT in older patients [2] [3] [4] [5] [6] , and a recent position statement from the International Society of Geriatric Oncology states that ASCT is appropriate for selected patients over the age of 60 years [7] , prospective data evaluating efficacy of salvage chemotherapy with intent to pursue transplant are lacking. The median age of patients with diffuse large B-cell lymphoma (DLBCL) at diagnosis is 70 years [8] , and as advanced age is associated with higher rates of primary treatment failure [9, 10] , defining the role of ASCT in older individuals is of great relevance.
The NCIC-CTG (now Canadian Cancer Trials Group, CCTG) LY.12 study was a randomized, phase III trial evaluating the optimum salvage chemotherapy regimen before ASCT for patients with relapsed or refractory aggressive lymphomas [11] . There was no upper age limit for study enrollment if patients were considered fit to proceed with high-dose therapy. This study showed GDP is non-inferior to DHAP with respect to response rate, and results in similar rates of successful stem cell mobilization, transplantation and event-free survival (EFS) after transplant, with less toxicity [11, 12] . We carried out this subgroup analysis to compare response rate, toxicity and outcomes for patients over the age of 60 years, including a cohort >65 years, to younger patients undergoing salvage therapy and ASCT.
Methods Patients
Patients eligible for CCTG LY.12 were age !16 years with relapsed or refractory aggressive lymphoma and ECOG performance status 0-3. There was no defined upper age limit for enrollment although patients had to be judged fit to proceed with ASCT, as described previously [11] . Patients with aggressive histology lymphoma had progressive or relapsed disease after one anthracycline-containing regimen; patients with transformed lymphoma were allowed up to three lines of chemotherapy [11] .
Study design and treatment
Patients were randomized 1:1 to receive two to three cycles of either outpatient gemcitabine, cisplatin and dexamethasone (GDP), or inpatient dexamethasone, cytarabine and cisplatin (DHAP) at 21-day intervals; the protocol was subsequently amended to add rituximab on day 1 of each cycle of GDP or DHAP for patients with CD20þ disease. Primary prophylaxis with granulocyte colony-stimulating factor to prevent febrile neutropenia (FN) after DHAP was allowed at the treating physician's discretion. At first randomization, patients were stratified for International Prognostic Index at relapse (rIPI), immunophenotype (B cell versus T cell), response to primary therapy (refractory, relapse <1 year or relapse >1 year), prior rituximab treatment and treating centre, but not by age.
Patients who achieved a complete or partial response (CR, CRu or PR) [13] were eligible to proceed to stem cell collection and transplant; those who achieved stable disease (SD) could proceed to ASCT at investigator discretion. Stem cell mobilization and collection, conditioning regimens, supportive care and use of post-transplant radiotherapy were carried out according to local transplant centre practice. Following transplant, patients with CD20þ lymphomas underwent a second randomization to rituximab maintenance (375 mg/m 2 every 2 months for six cycles) or observation [14] .
Study endpoints
Co-primary endpoints of the first randomization were overall response and transplantation rates between GDP and DHAP. The current analysis compares response and transplantation rates between patients aged 60.0 years, and those aged >60.0 years. Overall response rate was the proportion of randomized patients achieving CR, CRu or PR in each group (intention-to-treat analysis) [13] . Transplantation rate was calculated as the number of patients meeting criteria for successful stem cell mobilization (!2 Â 10 6 CD34þ cells per kg body weight) among those receiving at least one cycle of chemotherapy. Additional secondary endpoints included EFS, overall survival (OS), and toxicity, which are compared between younger and older patients in the current analysis. OS was measured from date of randomization until death; EFS was defined as time to disease progression, relapse after objective response, initiation of new therapy or death from any cause. Computed tomographic scans were carried out at 3, 7, 13 and 25 months post transplant. Toxicity was graded according to the Common Toxicity Criteria, Version 2.0. Quality of life was measured using the Functional Assessment of Cancer Therapy (FACT) instrument [15] , including a subscale for neurologic toxicity and a lymphoma-specific subscale [16] and was assessed at baseline, end of cycle one, middle and end of cycle two, and 1 month post ASCT.
Statistical analysis
Differences in response and transplantation rates between older and younger groups were compared using Fisher's exact test. EFS and OS were calculated according to Kaplan and Meier [17] and compared using the log-rank test [18] . In exploratory multivariate analysis, logistic regression and Cox proportional hazards models were used for categorical and time to event outcomes, respectively. Cumulative incidence of treatment-related mortality (TRM) was estimated by competing risks analysis [19] . All analyses were carried out using SAS software, version 9.2 (SAS Institute Inc., Cary, NC).
Results
Between August 2003 and November 2011, 619 patients with relapsed or refractory aggressive histology lymphomas were enrolled. Of these, 177 patients (28.6%) were age !60 years and 30 were age >65 (supplementary Figure S1 , available at Annals of Oncology online). The median age of younger and older patients was 51.2 (range, 19-60) and 63.7 (range, 60-74) years, respectively (Table 1) . ECOG performance status was 0 or 1 in 88.1% of older patients and 85.7% of younger patients. At study enrollment, similar proportions of older and younger patients had stage III/IV disease (74% versus 67%), elevated lactate dehydrogenase (LDH) (41.8% versus 41.6%) and >1 extranodal site of disease (22.6% versus 26.9%, respectively). More patients in the older cohort had three or more IPI risk factors, compared with the younger group (58.8% versus 24.2%, respectively). Before study enrollment, 128 older patients (72.3%) and 292 younger patients (66.1%) had prior rituximab treatment. Twenty-six percent of older patients had no response or progressive disease following primary therapy, compared with 33.5% among younger patients.
The overall response rate for all patients following two cycles of salvage chemotherapy was 44.6%. Of the older individuals, 48.6% achieved a response, compared with 43% of younger patients (difference 5.6%, 95% CI À3.1% to 14.3%, P ¼ 0.21). By treatment arm, the response rate for older and younger patients receiving GDP was 44.3% and 45.5%, respectively (difference À1%, 95% CI À11% to 13%, P ¼ 0.85), and 52.8% versus 40.5% for DHAP (difference 12.4%, 95% CI 0.1% to 24.6%, P ¼ 0.047) ( Table 2 ). Multivariate analysis demonstrated that response to first-line therapy (!PR), duration of response to first-line therapy >1 year, and absence of B symptoms at relapse were independently predictive of response to salvage chemotherapy. Age, treatment arm, prior treatment with rituximab and additional tumor-and patient-specific characteristics were not predictive (supplementary Table S2 , available at Annals of Oncology online).
In patients aged >60.0 years, 84.2% of PBSC mobilization attempts were successful, compared with 85.8% for younger patients (Table 2) . Transplantation rates were also similar: 50.3% for patients >60.0 years, compared with 49.8% for younger patients (difference 0.5%, 95% CI À8.2% to 9.2%, P ¼ 0.87). For those patients who successfully underwent transplantation, there was no difference in disease status at the time of ASCT between older and younger patients, with 26.1% and 23.7% of old versus young patients, respectively, transplanted in CR/Cru, 45.5% versus 45.7% in PR and 27.3% versus 30.6% SD. In multivariate analyses, achieving a response to primary therapy (!PR), duration of prior response >1 year, DLBCL histology, ECOG performance status 1, normal LDH and absence of B symptoms at relapse were all independently predictive of proceeding to transplant (supplementary Table S2 , available at Annals of Oncology online).
After a median follow-up of 53 months, 4-year OS was 36% and 40% (P ¼ 0.42) for patients age >60.0 and 60.0 years, respectively ( Figure 1) . Four-year EFS was likewise similar between the older and younger cohorts (20% versus 28%, P ¼ 0.43, Figure 1 ). Furthermore, when only patients who successfully underwent ASCT were considered, 4-year OS was not significantly different between groups: 66% for patients 60.0, and 55% for those > 60.0 years (HR 1.28, 95% CI 0.87 to 1.91, P ¼ 0.21). Four-year EFS was 31% for older patients and 52% for younger patients (hazard ratio 1.39, 95% CI 0.99-1.94); however, this did not reach statistical significance (P ¼ 0.054, supplementary Figure S2 , available at Annals of Oncology online). Multivariate analyses demonstrated response to primary therapy (!PR), duration of response to front-line therapy >1 year, DLBCL or transformed histology, normal LDH, absence of B symptoms at relapse and 1 extranodal site of disease were predictive of OS and EFS (supplementary Table S3 , available at Annals of Oncology online).
There was no significant difference in EFS at 48 months following transplantation between the oldest group of patients (age >65 years, n ¼ 23, EFS 31%) and those aged 60-65 years (n ¼ 64, EFS Figure S3 , available at Annals of Oncology online). Treatment-related toxicity, by per-protocol analysis, was not significantly different between older and younger patients for rates of FN or hospitalization due to adverse events. Thirty percent of older patients experienced an episode of FN, compared with 23% of younger patients (P ¼ 0.053) (supplementary Table  S4 , available at Annals of Oncology online). This difference was largely accounted for by more events in the DHAP arm, where FN occurred in 42.5% of older patients, compared with 18.4% for those receiving GDP (difference 24.1%, 95% CI À10.4 to À37.8%, P ¼ 0.005). Rates of FN for younger patients were likewise significantly different between treatment arms: 17.4% for GDP and 28.6% for DHAP (difference 11.2%, 95% CI À3.3% to À19.1%, P ¼ 0.005). Hospitalization rates for adverse events following salvage therapy were not significantly different between age cohorts: 37.9% for older patients versus 32.1% for younger (P ¼ 0.17). Older patients treated with GDP had a hospitalization rate of 29.9% compared with 46.0% for those receiving DHAP (difference 16.1%, 95% CI À1.7% to À30.5%, P ¼ 0.03); for patients aged 60.0 years, admission rates were 26.5% and 37.8% for GDP and DHAP, respectively (difference 11.3%, 95% CI À2.5% to À20.1%, P ¼ 0.01). Other grade 3 or 4 hematologic and non-hematologic toxicities were comparable between younger and older patients (supplementary Table S5 , available at Annals of Oncology online).
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There were eight salvage therapy-related deaths among patients aged >60.0 years [8/174 (4.60%), 95% CI, 1.46-7.58), and five deaths in those aged 60.0 years [5/436 (1.15%), 95% CI, 0.15-2.12]. Following ASCT, the 1-year risk of TRM for patients aged >60.0 years was 8.06% (n ¼ 88; 95% CI, 3.97-16.36), and 1.85% for those aged 60.0 years (n ¼ 219; 95% CI, 0.70-4.88) (supplementary Figure S4 , available at Annals of Oncology online). A description of transplant-related deaths is provided in supplementary Table S6 , available at Annals of Oncology online.
Quality of life assessment showed that individuals aged >60.0 years had worse scores at baseline compared with younger patients in multiple domains (FACT-TOTAL and FACT-LYMPHOMA, P < 0.005). Compared with baseline, mean change scores following salvage chemotherapy were not significantly different between younger and older patients. 
Discussion
This is the first prospective evaluation of the outcome of salvage therapy with the intention to pursue ASCT in patients aged >60 years with relapsed or refractory aggressive lymphoma. Our data, in contrast to some transplant registry reports [20] , show similar results for salvage therapy and for ASCT in older and younger patients and suggest that exclusion of older patients from transplant-based approaches, out of concern over increased toxicity and transplant-related mortality, may be unfounded. Age remains a significant prognostic factor in the era of rituximabbased chemotherapy for DLBCL [9] , and expanding the application of ASCT to include carefully selected older patients may improve survival outcomes, where current treatment strategies are often less effective.
Although previous reports demonstrate inferior PFS and OS among patients aged >60 years undergoing initial treatment of DLBCL [21] , and for patients >70 years compared with those aged 60-69 years [22, 23] , our results suggest no difference in OS between older and younger individuals undergoing salvage chemotherapy and ASCT for relapsed or refractory aggressive lymphoma. We observed similar response rate and EFS, despite patients in the older cohort having higher rIPI scores, and therefore an expected lower response rate and greater likelihood of relapse [24] .
Mortality from salvage chemotherapy was slightly higher among older patients (4.52% versus 1.13%); however, this did not contribute to inferior OS. Although the number of events was small, the majority of early deaths occurred among patients receiving DHAP, in keeping with the greater overall toxicity observed with this regimen compared with GDP [11] . In the current analysis, GDP was associated with a lower incidence of FN and hospitalization for adverse events in the older patient population, consistent with the overall results of the LY.12 study, with similar response and transplantation rates, suggesting that GDP is the preferred regimen for older patients considered for ASCT.
For those who did successfully undergo ASCT, 1-year TRM was higher in the older cohort. Importantly, this finding did not result in an inferior 4-year OS compared with younger patients. However, this observation does underscore the need for careful selection of appropriate patients for intensive treatment approaches such as ASCT. One limitation of our study is the small number of patients included over the age of > 65 years, which may limit the generalizability of the results to older individuals. As only 28% of patients enrolled in this trial were aged >60.0 years, with fewer >65 years, the power to detect a difference in outcomes is limited. Although we did not observe a difference in outcome for patients aged 60-65 and those aged >65 years, one large retrospective analysis demonstrated a significant increase in relapse rate with increasing age among patients transplanted over the age of 60 years [25] . Older patients in our study were highly selected, although no formal assessment of fitness or comorbidities was required before enrollment. To date, retrospective studies investigating the value of comorbidity scores in predicting outcomes for older patients undergoing ASCT have shown them to be of uncertain utility. Hosing et al. [26] demonstrated that, although hematopoietic cell transplantation comorbidity index (HCT-CI) scores >2 predicted for higher grade 3-5 toxicity among patients over the age of 65 years undergoing ASCT for lymphoma, this did not predict OS. In contrast, Elstrom et al. [27] reported high TRM and poor OS among patients over the age of 69 years with high-risk HCT-CI scores. Others have reported no correlation between high-risk comorbidity scores and OS, PFS, or TRM [5, 28, 29] ; prospective studies of the predictive value of comorbidity indices in selecting older patients for salvage therapy and ASCT are needed.
In summary, this subgroup analysis of the CCTG LY.12 randomized trial suggests that older individuals derive comparable benefit from transplant-based treatment to younger patients. The similar response and transplantation rates, EFS and OS between patients over and under the age of 60 years, recommends that patients not be excluded from potentially curative ASCT on the basis of age alone. Consideration of physiologic age and comorbidities should be used in identifying patients considered ineligible for intensive therapy, and the manner in which to best do this requires prospective evaluation.
